Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. COST
3. SPY
4. MSFT
5. RMR
6. RXT
7. AAPL
8. MU
9. MDA
10. LEVI

Go back to Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

Vertex (VRTX) PT Raised to $125 at Credit Suisse; Raise Probability of Triplet to 75%

April 28, 2017 6:26 AM EDT

Credit Suisse raised its price target on Vertex (NASDAQ: VRTX) to $125.00 (from $108.00) while maintaining a Outperform rating.

Analyst Alethia Young raised their probability of success to 75% from 50% to the triplet in the HetMin population. They model $2.1B in peak sales in HetMin.

... More